知镜 Cognispect · 医学文献与研究工作台

Illuminating metabolic disorders with engineered fluorescent carbon dots: advances in biosensing to therapeutics.

Prasad G, Srivastava M, Devi S, Tripathi P, Singh V.
RSC advances · 2026-11-04 · PMID 42985092

文献摘要

Metabolic diseases, including diabetes, obesity, non-alcoholic fatty liver disease, dyslipidemia, and hyperuricemia, represent a major global health challenge, necessitating early diagnosis and effective therapeutic strategies. Conventional approaches may face limitations in sensitivity, specificity, and targeted delivery. In this context, carbon dots have attracted considerable interest as versatile nanoplatforms for metabolic biomarker detection, bioimaging, and potential therapeutic applications. Carbon dots are carbon-based, quasi-spherical nanomaterials characterized by tunable photoluminescence, relatively low toxicity, ease of synthesis, and promising biocompatibility. These properties support their investigation for detecting metabolic biomarkers, including uric acid, glucose, and cholesterol, through sensitive and selective fluorescence-based approaches. Their demonstrated sensing capabilities in controlled environments and spiked biological samples provide a foundation for further investigation toward clinical applications. Similarly, carbon dot-based bioimaging of metabolically relevant organs, such as the pancreas and liver, and their antioxidant and drug-delivery properties highlight their potential for advancing future diagnostic and therapeutic strategies. Advances in surface engineering and heteroatom doping ( e.g. , nitrogen, sulfur, and phosphorus) have expanded the potential biomedical applications. CDs are also being investigated as carriers for antidiabetic and lipid-regulating agents, with the potential to improve drug loading, delivery, and release. Furthermore, certain CDs exhibit antioxidant activity that may help mitigate oxidative stress associated with metabolic disorders. These developments highlight the emerging potential of CDs in integrated diagnostic-and-therapeutic, or theranostic, platforms. This review critically examines the applications of CDs in acquired metabolic disorders, emphasizing sensing mechanisms, analytical performance, biological validation, and emerging therapeutic strategies. It also discusses key challenges, including biosafety, biodistribution, pharmacokinetics, long-term toxicity, reproducibility, scalable production, and the gap between laboratory-based findings and clinical translation. Further validation in appropriate biological models and clinical samples is essential before their diagnostic and therapeutic efficacy can be established.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。